Clinical trials: Coronary
Immune Deficiency Disorders, Severe Combined Immunodeficiency
Immune Disorder HSCT Protocol
This study hypothesizes that a reduced intensity immunosuppressive preparative regimen will establish engraftment of donor hematopoietic cells with acceptable early and delayed toxicity in patients with immune function disorders.
- Conditions
- Immune Deficiency Disorders, Severe Combined Immunodeficiency, Chronic Granulomatous Disease, X-linked Agammaglobulinemia
- Trial name
- NCT01821781
- Testing
- Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Washington University School of Medicine
Heart Failure, Healthy Volunteer
Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients
To evaluate the safety and tolerability of ascending single (Part A) and ascending multiple (Part B) doses of AMG 986 in healthy adults and of ascending multiple oral doses of AMG 986 in heart failure patients (Part C).
- Trial name
- NCT03276728
- Testing
- AMG 986 IV, AMG 986 PO
- Where
- 25 sites in United States, Australia and 7 more
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Amgen
Hypoplastic Left Heart Syndrome, Tricuspid Atresia
Sildenafil After the Fontan Operation
In this study, the investigators will evaluate the effect of sildenafil on exercise tolerance in patients with a single cardiac ventricle who have undergone the Fontan operation.
- Trial name
- SAFO (NCT00507819)
- Testing
- Sildenafil
- Volunteers
- 28 people
- Sponsor
- Children's Hospital of Philadelphia
Depression, Generalized Anxiety Disorder
A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients
For this trial, the investigators propose a prospective trial of a collaborative care program to identify and treat depression, generalized anxiety disorder, and panic disorder among patients admitted to the hospital for an acute…
- Conditions
- Depression, Generalized Anxiety Disorder, Panic Disorder
- Trial name
- MOSAIC (NCT01201967)
- Testing
- Collaborative care, Usual care
- Where
- United States
- Volunteers
- 183 people
- Sponsor
- Massachusetts General Hospital
Chronic Heart Failure
Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure
The purpose of this study was to assess the safety of repeat doses of serelaxin in chronic heart failure.
- Trial name
- RELAX-REPEAT (NCT01982292)
- Testing
- RLX030 (serelaxin)
- Where
- 52 sites in United States, Australia and 11 more
- Volunteers
- 321 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes, Hypertension
Scripps Wired for Health Monitoring Study
People with chronic diseases such as diabetes, hypertension (high blood pressure) and cardiac (heart) arrhythmias tend to go to the doctor more often and have more tests done than those without those diseases.
- Conditions
- Diabetes, Hypertension, Cardiac Arrhythmia
- Trial name
- NCT01975428
- Testing
- DM Pgm + device, Control
- Where
- United States
- Volunteers
- 182 people
- Sponsor
- Scripps Translational Science Institute
Chronic Heart Failure
Splanchnic Nerve Block for Therapy of Chronic Heart Failure (Splanchnic III)
Splanchnic vasoconstriction may contribute to decompensation of chronic heart failure (HF) via volume redistribution from the splanchnic vascular bed to the central compartment.
- Trial name
- NCT04575428
- Testing
- Splanchnic nerve block
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Duke University
Sinus Node Dysfunction
Registry to Improve the Adoption of Consensus Treatment Guidelines (IMPROVE Brady)
Registry to Improve the Adoption of Consensus Treatment Guidelines (IMPROVE Brady)
- Trial name
- IMPROVE Brady (NCT01643707)
- Testing
- Evidence based guidelines and tools
- Where
- 21 sites in Argentina, Bangladesh and 5 more
- Volunteers
- 1,342 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure
Reveal LINQ™ Heart Failure
The purpose of the LINQ™ HF study is to characterize Reveal LINQ™ derived data from patients with heart failure by assessing the relationship between changes in LINQ™ derived data and other physiologic parameters with subsequent…
- Trial name
- LINQ HF (NCT02758301)
- Testing
- Reveal LINQ™ Insertable Cardiac Monitor (ICM)
- Where
- 19 sites in United States
- Volunteers
- 112 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Valvular Heart Surgery
Efficacy of Prothrombin Complex Concentrate Reducing Perioperative Blood Loss in Cardiac Surgery
This non-inferiority, randomized controlled trial aims to evaluate whether coagulation-guided low-dose four-factor prothrombin complex concentrate (PCC) is non-inferior to fresh frozen plasma (FFP) in reducing cumulative chest…
- Trial name
- NCT04244981
- Testing
- Prothrombin Complex Concentrate, Human, Fresh Frozen Plasma
- Where
- 2 sites in China
- Volunteers
- 476 people
- Sponsor
- SHI Jia
Heart Failure
Strategies for Aggressive Central Afterload Reduction in Patients With Heart Failure
Heart failure (HF) is the leading cause of hospitalization among Americans over the age of 65 years, affecting greater than 5 million in the U.S. alone.
- Trial name
- SACAR (NCT00588692)
- Testing
- SphygmoCor
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Mayo Clinic
Coronary Artery Bypass Graft Surgery, Presence of Heparin/Platelet Factor 4 Antibody
Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion
Heparin/Platelet Factor 4 (PF4) antibody testing will be performed in subjects who have just undergone coronary artery bypass grafting (CABG) surgery.
- Trial name
- NCT01246011
- Testing
- Argatroban and warfarin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Massachusetts General Hospital
Atrial Fibrillation, Cardioversion
Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation
Patients with atrial fibrillation undergoing cardioversion will be randomized to undergo transesophageal echocardiography or they will receive warfarin for 3 weeks with an international normalized ratio (INR) value between…
- Conditions
- Atrial Fibrillation, Cardioversion, Cerebrovascular Stroke
- Trial name
- AFTER-CV (NCT01924065)
- Testing
- Cardioversion, Oral Anticoagulant
- Where
- Turkey (Türkiye)
- Volunteers
- 112 people
- Sponsor
- Suleyman Demirel University
Mitral Valve Regurgitation, Mitral Regurgitation
The MitraClip® EXPAND Study of the Next Generation of MitraClip® Devices
The MitraClip EXPAND Study (A Contemporary, Prospective Study Evaluating Real-world Experience of Performance and Safety for the Next Generation of MitraClip Devices) is designed to confirm the safety and performance of the…
- Trial name
- NCT03502811
- Testing
- MitraClip NTR/XTR System
- Where
- 57 sites in United States, Germany and 6 more
- Volunteers
- 1,041 people
- Sponsor
- Abbott Medical Devices
Heart Failure, Cardiovascular Disease
Rhode Island Diastolic Dysfunction - Heart Failure
To study the hypothesis that treating patients with underlying diastolic dysfunction with oral Kuvan® (BH4, also known as tetrahydrobiopterin) in addition to current best practices will improve metabolic and echocardiographic…
- Trial name
- RIDD-HF (NCT02353312)
- Testing
- Kuvan
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Providence VA Medical Center
Anterior Wall Acute Myocardial Infarction
Evaluation of the Delivery of Optimized Supersaturated Oxygen Therapy to Treat Patients With an Acute Heart Attack
The purpose of this study is to evaluate the feasibility of the delivery of SuperSaturated Oxygen (SSO2) Therapy for 60 minutes selectively into the left main coronary artery (LMCA).
- Trial name
- NCT01630707
- Testing
- SuperSaturated Oxygen (SS02) Therapy
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- TherOx
Myocardial Infarction, Heart Failure
Study of Oral PG-116800 Following a Heart Attack
The main purpose of the study is to test whether a possible new drug (called PG-116800) can prevent some of the damage to heart muscle in patients who have had a heart attack.
- Conditions
- Myocardial Infarction, Heart Failure, Heart Enlargement
- Trial name
- NCT00067236
- Testing
- PG-116800 (given as PG-530742)
- Where
- 52 sites in United States, Canada and 1 more
- Volunteers
- 253 people
- Sponsor
- Procter and Gamble
Coronary Artery Bypass, Antiplatelet Agents
Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery
The study population will include all patients undergoing elective CABG. Consent and randomization will occur before surgery. Total 500 patients undergoing elective CABG will be randomly assigned into three groups with 1:1:1…
- Trial name
- DACAB (NCT02201771)
- Testing
- Aspirin, Ticagrelor
- Where
- 6 sites in China
- Volunteers
- 500 people
- Sponsor
- Ruijin Hospital
Marfan Syndrome
Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome
Marfan syndrome is a hereditary connective tissue disorder. Many individuals with this condition die because of the associated heart and blood vessel abnormalities.
- Trial name
- NCT00429364
- Testing
- Losartan Potassium, Atenolol
- Where
- 26 sites in United States, Belgium and 1 more
- Volunteers
- 608 people
- Sponsor
- Carelon Research
Atrial Fibrillation, Stroke
Patient Convenience Study (RE-SONANCE)
The aim of this non-interventional study is to describe patient's perception of anticoagulant treatment when using Pradaxa to prevent stroke and systemic embolism while suffering from atrial fibrillation (according to its…
- Trial name
- NCT02684981
- Where
- 12 sites in Austria, Bulgaria and 10 more
- Volunteers
- 9,472 people
- Sponsor
- Boehringer Ingelheim